San Diego-based Amira Pharmaceuticals, the developer of treatments for lung diseases, said today it has filed an application to the FDA to start clinical trials of a new drug for fibrotic disorders. The company is seeking to run tests in healthy volunteers on AM152, an experimental blocker of a target called LPA1.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
